Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome
about
Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserineHigh affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin IIPlasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesisStructure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.A Novel Dimeric Inhibitor Targeting Beta2GPI in Beta2GPI/Antibody Complexes Implicated in Antiphospholipid SyndromePathophysiology of the antiphospholipid syndromeDomain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome.Protein extraction and 2-DE of water- and lipid-soluble proteins from bovine pericardium, a low-cellularity tissueAntigen and substrate withdrawal in the management of autoimmune thrombotic disorders.Plasma gelsolin facilitates interaction between β2 glycoprotein I and α5β1 integrinThe vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamicsBiophysical analysis of the interaction of the serum protein human β2GPI with bacterial lipopolysaccharide.Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I.Human apolipoprotein H may have various orientations when attached to lipid layer.Autoantibodies directed against domain I of beta2-glycoprotein I.Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1.Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particlesVariability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs.Contamination of therapeutic human immunoglobulin preparations with apolipoprotein H (β2-glycoprotein I).β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus.Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease.Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I.β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome.Relative quantification of several plasma proteins during liver transplantation surgery.Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathwayEvaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies.Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.Reduced beta 2 glycoprotein I improve diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathwayNovel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I.Antiphosphatidylserine antibodies and reproductive failure.Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor VBinding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies.Human β2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced injury and inflammationRecombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H)Annexin A2 heterotetramer: structure and functionInterpretation of ensembles created by multiple iterative rebuilding of macromolecular modelsHydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.
P2860
Q21132365-1C468C10-6707-49B8-876C-06E01551CAEDQ22254095-2B79CF67-E240-4A89-8381-748F3186753DQ24293734-319BF332-9644-4649-8B68-D1551CEB403EQ24543850-C26D55E3-1A26-441F-932A-CECAC817C941Q27666379-2D191B42-71BF-4717-B76A-D3589151F7E9Q28267421-A6D9B502-24D7-499F-9551-7B46C1E46686Q28291393-BED0382D-8716-40D0-B91A-A6C89DF6BD4DQ33341518-4C1DC60C-B750-4D05-B7C5-FEE552AE865DQ33382797-211C036C-A6E7-4FFB-A454-966C23058374Q33403225-E528C5FF-1F86-47B4-B099-9E75CC7975ABQ33511345-6711D706-474D-4939-9557-56BB6B223D87Q33643329-6548AFDF-377D-452D-A30A-CE971609D546Q33729006-5FA446E5-F67F-470C-838D-C3B1D5124454Q33780553-77131869-2676-4252-9E07-4E3FDCD74D01Q33844273-2C8DB6D9-366D-41C8-AC2C-E5CEDB7145A1Q34178498-6ED1DC20-7C30-45AF-BB5D-2F7B924CB125Q34467454-7D51C680-E3DB-44A2-B141-AAE22ACEE14EQ34474881-21C9102F-68A4-4548-94A0-3423583BC1A9Q34682186-ACADBDB8-76B7-476C-AC4A-D3D58C90C2E0Q34949493-7852256E-AD66-4887-9BBD-632DCD9498F3Q35019430-FBE2122C-3C72-4428-8907-0DEC2EB24A93Q35086349-69F7E026-462A-4E11-A7F0-1BD6255DE288Q35181703-C0019C94-2038-4B99-8087-1907213418C8Q35419865-3C1A3AF4-DA5F-4C1B-80FE-DB9988EAA6E7Q35584256-F8C91FEE-C7A5-44FE-8522-0F8F12DD34A5Q35610458-C1E60334-D0D0-4918-8427-FBFA7C9288A0Q35631986-B5462B71-1656-4001-A6D2-6984157504BEQ35709692-C1AEBB8D-EFAC-4715-9396-5D29EFF97F6CQ35792021-12C7260E-00F2-45C8-A151-E0BBC5CF4E76Q35870605-2CA330B0-3A9E-4AAB-B8F1-795776E4345FQ35895238-C18F9215-F890-41F3-9D22-BC980BF87A54Q35918365-FB173087-C19E-4DB1-8818-6B9543632942Q35921636-B24618DA-5DA0-40CE-AC0B-14D0A8508505Q36225236-812BAD80-28EE-4702-8B74-16D02BD766D1Q36287542-02168072-7D97-45F4-96B4-ACCA28DB7079Q36590359-421A5B85-C48E-4D7B-90CA-BEBF297395D3Q36596956-AD19DA94-EB46-492D-A38A-89A795C75582Q36790362-17AAA210-5868-4CFA-914B-8808814AB090Q36790438-816438AB-AAF6-44FE-8C5B-8EBF7552A45AQ36843689-3AE20305-4DBE-41A4-AA44-F5C4F45AEC85
P2860
Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Crystal structure of human β2- ...... the antiphospholipid syndrome
@ast
Crystal structure of human β2- ...... the antiphospholipid syndrome
@en
Crystal structure of human β2- ...... the antiphospholipid syndrome
@nl
type
label
Crystal structure of human β2- ...... the antiphospholipid syndrome
@ast
Crystal structure of human β2- ...... the antiphospholipid syndrome
@en
Crystal structure of human β2- ...... the antiphospholipid syndrome
@nl
prefLabel
Crystal structure of human β2- ...... the antiphospholipid syndrome
@ast
Crystal structure of human β2- ...... the antiphospholipid syndrome
@en
Crystal structure of human β2- ...... the antiphospholipid syndrome
@nl
P2093
P3181
P356
P1433
P1476
Crystal structure of human β2- ...... the antiphospholipid syndrome
@en
P2093
G M Kostner
K Diederichs
R Schwarzenbacher
P304
P3181
P356
10.1093/EMBOJ/18.22.6228
P407
P50
P577
1999-11-15T00:00:00Z